A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders

NCT06705530 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

58

Enrollment

NETWORK

Sponsor class

Conditions

Non-Hodgkin Lymphoma, B-cell
Acute Lymphoblastic Leukemia ALL

Interventions

BIOLOGICAL: Hem101

Sponsor

National Research Center for Hematology, Russia